Clinical Trials Browser

Recruiting × Rectal Neoplasms × Capecitabine × Clear all

NCT04929028 2026-03-18

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase 2 Recruiting

Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT04808323 2026-03-16

MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

Phase 1 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06205485 2026-01-13

NEO-RT

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT04095299 2026-01-08

WW3

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT07068763 2026-01-06

mRCAT-E

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT04703101 2025-11-10

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Phase 1 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05576480 2025-08-28

SPARC

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06507371 2025-06-26

mRCAT-III

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06780787 2025-06-26

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06417476 2025-03-19

Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06210971 2025-03-13

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06204094 2025-01-07

CASINOs

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05628038 2024-10-01

TORCH-R

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT06266832 2024-02-20

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05877573 2023-07-05

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

Phase NA Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05815303 2023-04-18

XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05136326 2023-03-01

CATARTIC

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05201430 2022-03-04

RCNAC

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT04288999 2020-06-04

JCOG1801

Phase 3 Recruiting

Gastrointestinal

Rectal Neoplasms